News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Innate Therapeutics Initiates Phase 2 Testing of MIS416 in Patients With Progressive Multiple Sclerosis
October 11, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
AUCKLAND, New Zealand--(BUSINESS WIRE)--Innate Therapeutics today announced that the company has begun treating patients in a Phase 2a clinical study of its lead molecule, MIS416, in patients with progressive multiple sclerosis (MS).
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase II
Europe
Australia
MORE ON THIS TOPIC
Podcast
JPM26 Recap, Novo’s Oral Wegovy Soars as Lilly’s Orforglipron Is Delayed, IPOs Return
January 21, 2026
·
1 min read
·
Heather McKenzie
Career Advice
Going With the Flow: Finding Success in Academic and Biotech Research Cultures
January 21, 2026
·
6 min read
·
Manali Shah
Cancer
Moderna, Merck Show Long-Term Survival for mRNA-Keytruda Combo
January 20, 2026
·
2 min read
·
Annalee Armstrong
Lymphoma
AbbVie, Genmab’s Bispecific Misses Key Overall Survival Endpoint in Phase III Lymphoma Study
January 19, 2026
·
2 min read
·
Tristan Manalac
